The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas

References

• Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg–Reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Canc 1982;30:445-59
   PubMed Web of Science ®Google Scholar
• Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leukemia Lymphoma 2011;52:1641-54
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – Non-Hodgkin’s Lymphomas. National Comprehensive Cancer Network, 2014
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – Hodgkin Lymphoma. National Comprehensive Cancer Network, 2014
   Google Scholar
• Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013;6:CD009411
   PubMedGoogle Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Fanale M, Advani R, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012;17:1073-80
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii70-5
   PubMed Web of Science ®Google Scholar
• Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematologic Malignancy Rep 2010;5:140-7
   PubMed Web of Science ®Google Scholar
• Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnol 2012;30:631-7
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Steinwand M, Wezler X, et al. CD30 as a therapeutic target for lymphoma. BioDrugs 2014;28:181-209
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs 2013;73:371-81
   PubMed Web of Science ®Google Scholar
• Bonthapally V, Wu E, Macalalad A, et al. Antitumor activity of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT): meta-analysis comparison. Haematologica 2013;98(Suppl 2):1-64
   PubMedGoogle Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute, 2012
   Google Scholar
• World Health Organization – International Agency for Research on Cancer. Hodgkin lymphoma – estimated incidence, mortality and prevalence for both sexes, 2012. 2012. Available at: http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=37 [Last accessed 11 August 2014]
   Google Scholar
• World Health Organization – International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx [Last accessed 20 September 2014]
   Google Scholar
• Gloeckler Ries LA, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2003. National Cancer Institute, 2006. Accessed May 14, 2014. Available at: http://seer.cancer.gov/csr/1975_2003/
   Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265-76
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117:4208-17
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:1506-14
   PubMed Web of Science ®Google Scholar
• Stanca O, Ciobanu AM, Lupu AR, et al. Onset risk factors and treatment response features of refractory hodgkin lymphoma. Maedica 2013;8:343-6
   Google Scholar
• Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin’s lymphoma. Oncologist 2007;12:156-67
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-9
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
   PubMed Web of Science ®Google Scholar
• Baculea S, Eaton J, Illidge T. Relapsed or refractory systemic anaplastic large-cell lymphoma (sALCL) – a burden of illness analysis. 17th Congress of the European Hematology Association (EHA), 14–17 June 2012, Amsterdam, The Netherlands
   Google Scholar
• Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95
   PubMed Web of Science ®Google Scholar
• Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Canc Cause Control 2008;19:841-58
   PubMed Web of Science ®Google Scholar
• ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects – a review. J Pathol 2003;200:4-15
   PubMed Web of Science ®Google Scholar
• Kinney MC, Higgins RA, Medina EA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med 2011;135:19-43
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Developing products for rare diseases and conditions. 2014. Available at: http://www.fda.gov/forindustry/DevelopingProductsforrareDiseasesConditions/default.htm [Last accessed 24 September 2014]
   Google Scholar
• European Medicines Agency. Orphan designation. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp [Last accessed 20 September 2014]
   Google Scholar
• US Food and Drug Administration. Designating an orphan product: drugs and biological products. 2013. Available at: http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/default.htm [Last accessed 20 September 2014]
   Google Scholar
• Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3-13
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:2065-71
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case–control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999;17:222-9
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473-8
   PubMed Web of Science ®Google Scholar
• Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2008;2008:326-33
   Google Scholar
• Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). ASCO Meeting Abstracts 2005;23(16 Suppl):6508
   Google Scholar
• Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin’s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biology Blood Marrow Transplantation 2012;18:451-7
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671-7
   PubMed Web of Science ®Google Scholar
• Vadakara J, Pro B. Targeting CD30 in anaplastic large cell lymphoma. Curr Hematologic Malignancy Rep 2012;7:285-91
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768-75
   PubMed Web of Science ®Google Scholar
• Jagasia M, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leukemia Lymphoma 2004;45:2261-7
   PubMed Web of Science ®Google Scholar
• Zamkoff KW, Matulis MD, Mehta AC, et al. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplantation 2004;33:635-8
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970-6
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995;80:357-66
   PubMed Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58
   PubMed Web of Science ®Google Scholar
• von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin’s disease. An immunohistochemical analysis of 208 reviewed Hodgkin’s disease cases from the German Hodgkin Study Group. Am J Pathol 1997;150:793-803
   PubMed Web of Science ®Google Scholar
• Falini B, Flenghi L, Fedeli L, et al. In vivo targeting of Hodgkin and Reed–Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992;82:38-45
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9
   PubMed Web of Science ®Google Scholar
• Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;339:1195-6
   PubMed Web of Science ®Google Scholar
• Hartmann F, Renner C, Jung W, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Canc Res 2001;7:1873-81
   PubMed Web of Science ®Google Scholar
• Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol 2003;14:729-36
   PubMed Web of Science ®Google Scholar
• Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-78
   PubMed Web of Science ®Google Scholar
• Fromm JR, McEarchern JA, Kennedy DA, et al. Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma. Blood 2010;116(Suppl 1):Abstract 1789
   Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Canc Res 2004;10:7063-70
   PubMed Web of Science ®Google Scholar
• Chen R, Smith SE, Ansell SM, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2013;122:4382
   Google Scholar
• US Food and Drug Administration. ADCETRIS – brentuximab vedotin injection, powder, lyophilized, for solution – highlights of prescribing information. 2013. Available at: http://www.accessdata.fda.gov/spl/data/8c6b15fa-c20d-b98f-b369-7323125b841d/8c6b15fa-c20d-b98f-b369-7323125b841d.xml
   Google Scholar
• Advani R, Oki Y, Shustov AR, et al. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study. J Clin Oncol 2012;30(Suppl):Abstract 8070
   Google Scholar
• Zinzani P, Sasse S, Radford J, et al. Brentuximab vedotin in relapsed/refractory (RR) Hodgkin lymphoma (HL) and RR systemic anaplastic large-cell lymphoma (sALCL): a review of international experience in the Named Patient Program (NPP). Haematologica 2013;98(Suppl 2):1-64
   PubMedGoogle Scholar
• Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 2013;21:895-903
   PubMed Web of Science ®Google Scholar
• Blum KA, Smith M, Fung H, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. ASCO Meeting Abstracts 2009;27:8531
   Google Scholar
• Saini KS, Azim HA Jr, Cocorocchio E, et al. Rituximab in Hodgkin lymphoma: is the target always a hit? Canc Treat Rev 2011;37:385-90
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311-19. https://doi.org/http://www.nejm.org/doi/full/10.1056/NEJMoa1411087
   Google Scholar
• Seattle Genetics I. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial). 2014. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01100502 [Last accessed 25 June 2014]
   Google Scholar
• Northwestern University. Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/CD30+ and/or EBV+ Lymphomas. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01805037 [Last accessed 25 June 2014]
   Google Scholar
• City of Hope Medical Center. Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01393717 [Last accessed 25 June 2014]
   Google Scholar
• Memorial Sloan–Kettering Cancer Center. Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01508312 [Last accessed 25 June 2014]
   Google Scholar